Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
December 22, 2015 at 16:17 PM EST
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced it filed an amendment to its ongoing Phase 2 clinical study of MM-121 ...